Drug Trial Radar · NCT04636983
Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male Subjects
Last checked: Nov 19, 2026Latest source record: Feb 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Nov 9, 2020
Primary completion
Dec 12, 2021
Study completion Jan 20, 2022
Sponsor
- Lead sponsor
- BioVersys SASIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, single-centre, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single intravenous ascending doses of BV100 to healthy male subjects.
Conditions
- Healthy Subjects
Interventions
BV100Drug
Rifabutin IV
PlaceboDrug
Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- To investigate the safety and tolerability of single intravenous ascending doses of BV100 assessed by the nature, occurrence, and severity of treatment-emergent adverse eventsTime frame: 10 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nuvisan GmbH
Neu-Ulm, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.